Schrodinger(US:SDGR)2025-11-05 21:30Financial Performance - Total revenue reached $54.3 million, a 54% increase compared to the same period last year[11] - Software revenue grew by 28% to $40.9 million[11, 27] - Drug discovery revenue experienced significant growth, reaching $13.5 million[11, 27] - The company anticipates software revenue growth between 8% and 13% for the year[11] - Drug discovery revenue is projected to be in the range of $49 million to $52 million[11] - Software gross margins are expected to be between 73% and 75%[11] Strategic Updates - The company plans to complete Phase 1 dose escalation studies for SGR-1505 and SGR-3515[12, 31] - Initial Phase 1 data for SGR-3515 is expected in the first half of 2026[12, 25, 31] - The company is exploring strategic opportunities for SGR-1505 clinical development[12] - The company is phasing out independent clinical development activities[12]